Vedolizumab for acute gastrointestinal graft-versus-host disease: A systematic review and meta-analysis.

Front Immunol · 2022 · PMC9692080 · PMID 36439135

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Likewise, the use of vedolizumab was followed by a significantly improved complete response (CR) at 12 months (pooled CR = 27.27%, RR = 5.50, 95% CI = 1.01–29.95), yet the CR at 14 days and 28 days did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.